AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02542839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroStar TMS therapy
Description: Application of repetitious transcranial magnetic stimulation (TMS) pulses using NeuroStar device to a specific brain target at predefined stimulation parameters.
Study NCT02542839 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham NeuroStar TMS therapy
Description: Same procedure as real rTMS without stimulating the cerebral cortex.
Study NCT02542839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)
Description: All participants will receive a clinical assessment of dystonia severity by using the TWSTRS test.
Study NCT02542839 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)
Description: All participants will receive a clinical assessment of dystonia severity by using the TWSTRS test.
Study NCT02542839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Craniocervical Dystonia Questionnaire (CDQ-24)
Description: All participants will fill out the Craniocervical Dystonia Questionnaire (CDQ-24) quality of life questionnaire.
Study NCT02542839 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Craniocervical Dystonia Questionnaire (CDQ-24)
Description: All participants will fill out the Craniocervical Dystonia Questionnaire (CDQ-24) quality of life questionnaire.
Study NCT02542839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerebellar-brain Inhibition (CBI)
Description: All participants will have a measure of the cerebellar-brain inhibition(CBI) which will be conducted by using a TMS device determining the ability of the coil to activate the cerebellum.
Study NCT03344367 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JWCAR029
Description: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with JWCAR029 by intravenous (IV) injection.
Study NCT01957488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test Product 1
Description: Coloplast Test product 1 is a newly developed 1-piece ostomy appliance
Study NCT01957488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test Product 2
Description: Coloplast Test product 2 is a newly developed 1-piece ostomy appliance
Study NCT01957488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast SenSura
Description: SenSura 1-piece is the commercial available CE-marked SenSura 1-piece from Coloplast A/S.
Study NCT03086772 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Individuals in the Tai Chi intervention group will participate in a 12-week Tai Chi program (one hour per class, two classes per week, plus home practice for 12 weeks) led by an experienced Tai Chi Instructor, assisted by an undergraduate research assistant.
Study NCT03086772 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Light Exercise
Description: Individuals in the exercise control group will meet for a twice weekly class involving walking, weight training, stretching and health education (one hour per class, two classes per week for 12 weeks, taught by a trained graduate research assistant, assisted by an undergraduate research assistant.
Study NCT03407859 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sequential Treatment With different CART
Description: Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment in Relapsed/Refractory B-ALL
Study NCT01073995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenalog and Sensorcaine
Description: Kenalog: 40 mg/ml Sensorcaine 0.25%: 1cc
Study NCT02829723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLZ945
Description: BLZ945 administered orally as a capsule. Up to five alternative dosing schedules were evaluated: once per day (QD) 7 days on/7 days off (i.e., administer BLZ945 for 7 days and suspend for 7 days), QD 4 days on/10 days off, twice per day (BID) 4 days on/10 days off, once weekly (Q1W) QD and Q1W BID.~Each cycle consisted of 28 days.
Study NCT02829723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 400 mg administered via intravenous (i.v.) infusion every 4 weeks (Q4W)
Study NCT01073995 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Kenalog and Sensorcaine
Description: Kenalog: 40 mg/ml Sensorcaine 0.25%: 1cc
Study NCT01968798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 100mg enteric-coated aspirin, taken daily
Study NCT01968798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mg enteric-coated placebo, taken daily
Study NCT00814099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team approach to sedation management
Description: The team approach to sedation management includes the following:~* Team education and consensus on the use of sedatives~* Team identification of the patient's trajectory of illness and daily prescription of a sedation goal~* A nurse-implemented goal-directed comfort algorithm that guides moment-to-moment titration of opioids and benzodiazepines~* Team feedback on sedation management performance
Study NCT00814099 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual approach to sedation management
Description: The pediatric ICU will continue its usual approach to sedation management.
Study NCT02259751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUC 7483 CL
Study NCT02542839 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cerebellar-brain Inhibition (CBI)
Description: All participants will have a measure of the cerebellar-brain inhibition(CBI) which will be conducted by using a TMS device determining the ability of the coil to activate the cerebellum.
Study NCT02542839 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections
Description: All participants will receive Botulinum toxin(BoNT) injections as part of their standard of care
Study NCT02542839 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Botulinum toxin injections
Description: All participants will receive Botulinum toxin(BoNT) injections as part of their standard of care
Study NCT03007784 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS) / Comparison of current intensities
Study NCT03007784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS) / Comparison of current intensities
Study NCT00546325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: White opaque film-coated, for oral administration containing 20 mg of active rimonabant. Once daily before breakfast
Study NCT00546325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets. Once daily before breakfast
Study NCT04133103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: first ambulation at 4 hour after operation
Description: Two groups were conducted for first ambulation at 4 or 24 hours aftër operation
Study NCT02867514 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 1 session per day during 10 days (5 days per week during 2 successive weeks). Subjects will be monitored during tDCS for any side effects or adverse events.
Study NCT02867514 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 1 session per day during 10 days (5 days per week during 2 successive weeks). Subjects will be monitored during tDCS for any side effects or adverse events.
Study NCT01500564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anodal tDCS (device) Eldith DC-Stimulator
Description: tDCS applied to the motor cortex every day of two consecutive weeks (10 sessions) at 1 mA during 20 minutes. Conductive rubber covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased over 100 seconds.
Study NCT01500564 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Participants will receive sham tDCS over the primary motor cortex of the ipsilesional hemisphere during 20 minutes of motor training (10 consecutive sessions Monday-Friday during two weeks).
Study NCT06285669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesiotaping application
Description: kinesiotaping application
Study NCT00803101 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Beriplex® P/N (Kcentra)
Description: Intravenous infusion, dosage depending on baseline INR, amount of coagulation factor IX and body-weight.
Study NCT00803101 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh frozen plasma
Description: Intravenous infusion, dosage depending on baseline INR and body weight
Study NCT02473861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate intensity aerobic and resistance training. Five minutes each of warm-up, cool-down, balance and flexibility will also be performed.
Study NCT02354716 — intervention group
Intervention type: DEVICE
Intervention: EndoFLIP
Description: The Endolumenal Functional Lumenal Imaging Probe Imaging System is a technology developed to measure the dimensions \& function of a variety of hollow organs throughout the body. Since receiving FDA clearance for sale in the United States EndoFLIP has been used in a variety of clinical applications. We intend to investigate the potential clinical applications of EndoFLIP in the upper GI tract in patients with esophageal stenoses who require endoscopic therapy for benign esophageal strictures. The use of EndoFLIP to characterize a stricture pre- \& post- dilation may offer insight in to the clinical and endoscopic predictors of successful stricture dilation, \& what characteristics determine \& predict refractory \& recurrent strictures.
Study NCT03503539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mini percutaneous nephrolithotomy
Study NCT03503539 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde intrarenal surgery
Study NCT01679301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse Dose (Sleep Mode)
Description: SimplyGo Portable Oxygen Concentrator has two different modes of use 'Sleep Mode', or pulsed oxygen and continuous dose.
Study NCT01679301 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Dose
Description: SimplyGo Portable Oxygen Concentrator has two different modes of use 'Sleep Mode', or pulsed oxygen and continuous dose.
Study NCT00791323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac 0.4%
Description: One drop 4 times a day in the pre-operative eye beginning day 0 for 4 days
Study NCT00791323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubricating Eye Drop
Description: One drop 4 times a day in the operative eye beginning one day prior to the peripheral iridotomy and continuing until the day of IOL implantation
Study NCT02827318 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isomaltulose
Description: 75g Isomaltulose (low glycaemic load intervention)
Study NCT02827318 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 75g Glucose (high glycaemic load intervention)
Study NCT02827318 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sweetened water
Description: Sweetened water will be used as a control
Study NCT04672096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuronoff BASMATI Injectrode
Description: The 28 day temporary placement of a Basmati Injectrode does not result in unexpected levels of inflammation or encapsulation.
Study NCT01119014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: pill, 2,5-20 mg/day, maximum 16 weeks
Study NCT01119014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: pill, 50-600mg/day, maximum 16 weeks
Study NCT00792558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-817378
Description: Capsule, Oral, Dose escalation to a MTD from a starting dose of 25 mg, once daily, until disease progression/subject discontinuation
Study NCT03091673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: 0.5 or 1.0 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector
Study NCT00610974 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Body-weight supported treadmill training
Description: BWSTT for 3 times/week for 12 weeks. Each session, subjects will first complete a 10-minute warm-up period followed by 45 minutes of the assigned therapy. Rest breaks will be provided as needed, but subjects must complete 45 minutes of walking per session.
Study NCT00610974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body-weight supported treadmill training
Description: BWSTT for 3 times/week for 12 weeks. Each session, subjects will first complete a 10-minute warm-up period followed by 45 minutes of the assigned therapy. Rest breaks will be provided as needed, but subjects must complete 45 minutes of walking per session.
Study NCT03812211 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Supplement
Description: Examine the effects of a multi-faceted supplement comprised of vitamins, minerals and naturally occurring and plant extracts approved for consumption of in overweight/obese men and women
Study NCT03812211 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Examine the effects of a placebo supplement in overweight/obese men and women, compare to the active supplement
Study NCT04872244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: usage of mirena ( levonorgestrel releasing intrauterine device) in isthmocele
Description: usage of mirena ( levonorgestrel releasing intrauterine device) in isthmocele for postmenstrual spotting and do not have desire for fertility
Study NCT04872244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel Drug Implant Product
Description: intrauterine administration
Study NCT00659594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: 200µg Ciclesonide versus Placebo
Study NCT00659594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT05220007 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Humphrey visual field testing
Description: Perimetry was performed with the Humphrey Field Analyzer (Carl Zeiss Meditec Inc). Participants performed a 30-2 or a 24-2 Swedish Interactive Threshold Algorithm (SITA) standard test with stimulus size III, and standard Humphrey background luminance of 31.5 apostilbs. The participants were selected by simple random sampling to perform the HVF test with presbyopic collection lenses followed by without presbyopic collection lenses, or without presbyopic collection lenses followed by with presbyopic collection lenses. The power of presbyopic correction lens at the testing distance of 33 cm (the bowl radius) was auto-calculated according to the recommendation by the Humphrey Field Analyzer's manufacturer, depending on the current refractive error and the patient's age.
Study NCT05220007 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Humphrey visual field testing
Description: Perimetry was performed with the Humphrey Field Analyzer (Carl Zeiss Meditec Inc). Participants performed a 30-2 or a 24-2 Swedish Interactive Threshold Algorithm (SITA) standard test with stimulus size III, and standard Humphrey background luminance of 31.5 apostilbs. The participants were selected by simple random sampling to perform the HVF test with presbyopic collection lenses followed by without presbyopic collection lenses, or without presbyopic collection lenses followed by with presbyopic collection lenses. The power of presbyopic correction lens at the testing distance of 33 cm (the bowl radius) was auto-calculated according to the recommendation by the Humphrey Field Analyzer's manufacturer, depending on the current refractive error and the patient's age.
Study NCT04524143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical mobilization
Description: Cervical mobilization techniques were applied in the study. Within the scope of application; rotation with traction, lateral gliding, anterior-posterior gliding with traction, bridging and stroking techniques to the paravertebral muscles were used. Mobilization were performed at grade A (mobilization in painless joint range) and grade B (continuous stretching at the end of the joint range). The mobilization were applied during 10 minutes.~At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise
Study NCT04524143 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: There was no intervention in the control group during study. At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise
Study NCT04524143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control
Description: There was no intervention in the control group during study. At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise
Study NCT00157807 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: bipolar radiofrequency ablation of persistent and permanent AF
Study NCT03607201 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Routine care
Study NCT01031901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Skincerity
Description: Study subjects will apply a study product containing polyvinylidene fluoride coating alone to either facial angiofibromas or cutaneous neurofibromas
Study NCT01031901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Skincerity plus sirolimus/rapamycin
Description: Study subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to either facial angiofibromas or cutaneous neurofibromas
Study NCT01031901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Skinercity plus sirolimus/rapamycin
Description: Study subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to either facial angiofibromas or cutaneous neurofibromas
Study NCT02540785 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lenticule extraction
Description: Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction was released, the flap was opened using a thin, blunt spatula and the free refractive lenticule was subsequently grasped with a forceps and extracted, after which the flap was repositioned carefully
Study NCT02540785 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: small-incision lenticule extraction
Description: Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), make a small incision
Study NCT01052402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation
Description: Two vaccinations, 21 days apart, followed by a heterologous booster vaccination on Day 360
Study NCT02504437 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BMMSCs
Study NCT02504437 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: BMMSCs
Study NCT02504437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMMSCs
Study NCT00840008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: As per detailed protocol.
Study NCT01207323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEHD7945A
Description: MEHD7945A will be administered as specified in the individual arms.
Study NCT04235101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYD985 + Niraparib
Description: SYD985 powder for concentrate for solution for infusion Niraparib 100 mg per hard capsule
Study NCT03062059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravesical 2000mg/52.6ml gemcitabine instillation
Description: Intravesical 2000mg/52.6ml gemcitabine instillation during operation to prevent intravesical recurrence after radical nephroureterectomy in upper urinary tract urothelial carcinoma
Study NCT03062059 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Intravesical 52.6ml normal saline instillation after radical nephroureterectomy in upper urinary tract urothelial carcinoma